Kailera Therapeutics/$KLRA
1D1W1MYTD1Y5YMAX
About Kailera Therapeutics
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
- Ticker
- $KLRA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Waltham, United States
- Website
- www.kailera.com
KLRA Metrics
BasicAdvanced
$2.3B
-
-$2.25
-
-
Price and volume
Market cap
$2.3B
52-week high
$28.23
52-week low
$16.37
Average daily volume
543K
Financial strength
Current ratio
11.108
Quick ratio
10.959
Long term debt to equity
0.82
Total debt to equity
0.913
Profitability
EBITDA (TTM)
-312.878
Management effectiveness
Valuation
Price to book
2.06
Price to tangible book (TTM)
2.06
Price to free cash flow (TTM)
-10.285
Free cash flow yield (TTM)
-9.72%
Free cash flow per share (TTM)
-1.726
Growth
What the Analysts think about KLRA
Analyst ratings (Buy, Hold, Sell) for Kailera Therapeutics stock.
KLRA Financial Performance
Revenues and expenses
KLRA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.